Insulin degludec in Phase 3 trials
Related Articles
- Translating Continuous Glucose Monitoring Systems: Toys or Tools. De Block, Christophe // Current Diabetes Reviews;2008, Vol. 4 Issue 3, p157
The article discusses various reports published within the issue, including one on the importance of strict blood glucose control in critically ill patients and another by Braithwaite et al. on algorithms for intravenous insulin infusion.
- Absorption of isophane (NPH) insulin and its clinical implications. Lauritzen, Torsten; Pramming, Stig; Gale, Edwin A.M.; Deckert, Torsten; Binder, Christian // British Medical Journal (Clinical Research Edition);7/17/1982, Vol. 285 Issue 6336, p159
Examines the absorption of isophane insulin in diabetics. Correlation between insulin absorption and plasma insulin and blood glucose concentrations; Manifestation of a slower absorption at higher doses; Rate of plasma elimination halftime of insulin.
- Diabetes: 7 Myths and 7 Facts. // Tennessee Tribune;3/15/2012, Vol. 23 Issue 11, p2B
The article presents information on several myths and facts on various aspects of diabetes related to its diagnosis, insulin treatment and blood sugars.
- Insulin degludec in Phase 3 trials. Elliott, William T. // Infectious Disease Alert;May2011 Pharmacology Watch, p2
The article discusses a research study which claims that insulin degludec can achieve blood sugar control equivalent to daily-administered insulin glargine.
- Insulin degludec in Phase 3 trials. Elliott, William T. // Neurology Alert;May2011 Clinical Bri, p2
The article discusses results of a study which showed that insulin degludec, an ultralong-acting insulin, can be used three times week to achieve blood sugar control equivalent to daily insulin glargine.
- Comparison of the Soluble Basal Insulin Analog Insulin Detemir With NPH Insulin. Hermansen, Kjeld; Madsbad, Sten; Perrild, Hans; Kristensen, Allan; Axelsen, Mads // Diabetes Care;Feb2001, Vol. 24 Issue 2, p296
Presents a study which compared the blood glucose-lowering effect of insulin detemir with that of NPH insulin. Information on insulin detemir; Research design and methodology; Results and conclusions.
- Errata. Basu, R.; Breda, E.; Powell, C.C.; Dalla Man, C.; Basu, A.; Vittone, J.L.; Klee, G.G.; Arora, P.; Jensen, M.D.; Toffolo, G.; Cobelli, C.; Rizza, R.A. // Diabetes;Dec2003, Vol. 52 Issue 12, p3014
Presents a corrected reprint of an article published in the 2003 issue of the journal "Diabetes" on the role of insulin in the mechanisms of age-associated deterioration of glucose tolerance.
- Professional CGM management workflow. Watsky, Jay; Dluge-Aungst, Dawn // Endocrine Today;Feb2011, Vol. 9 Issue 2, p6
The authors discuss the use of professional continuous glucose monitoring (CGM) in insulin therapy.
- Glucose transporter recycling in response to insulin is facilitated by myosin Myo1c. Bose, Avirup; Guilherme, Adilson; Robida, Stacey I.; Nicoloro, Sarah M. C.; Zhou, Qiong L.; Jiang, Zhen Y.; Pomerleau, Darcy P.; Czech, Michael P. // Nature;12/19/2002-12/26/2002, Vol. 420 Issue 6917, p821
Insulin stimulates glucose uptake in muscle and adipocytes by signalling the translocation of GLUT4 glucose transporters from intracellular membranes to the cell surface. The translocation of GLUT4 may involve signalling pathways that are both independent of and dependent on...
